Advanced Technology Corporation

Az itteni vizsgálatok

Miről szól a helyszín 10 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Narcolepsy6 vizsgálat
• Eosinophilic oesophagitis1 vizsgálat
• HIV-fertőzés1 vizsgálat
• Tüdőrák1 vizsgálat

Fázis

• 1. fázis9 vizsgálat
• 3. fázis1 vizsgálat

Állapot

• Lezárult8 vizsgálat
• Toboroz2 vizsgálat

Fő szponzor

• Bioprojet Pharma7 vizsgálat
• Merck Sharp & Dohme LLC2 vizsgálat
• Pfizer1 vizsgálat

Futó vizsgálatok

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Pfizer· Forrás

• Toboroz

  Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

  2024-512722-28-00· 1. fázis· Bioprojet Pharma· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Eosinophilic oesophagitis1 toboroz
• Tüdőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

  2025-520980-41-00· 1. fázis· Bioprojet Pharma· Forrás

• Lezárult

  Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

  2024-513383-26-00· 1. fázis· Bioprojet Pharma· Forrás

• Lezárult

  Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

  2024-512355-20-00· 1. fázis· Bioprojet Pharma· Forrás

• Lezárult

  MK-8507 Extended Multiple Dose Study

  2023-506697-12-00· 1. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Open label, single-center, four-part registration pharmacokinetic study: Part I: Pilot 2-way cross-over randomized, comparative pharmacokinetic study of a new gastro-resistant 20 mg pitolisant hydrochloride formulation versus the reference formulation, after a single 20 mg oral administration in twelve healthy subjects, in order to evaluate the adequate sample size to demonstrate the bioequivalence. Part II: One sequence cross-over, drug-drug interaction pharmacokinetic study between a proton pump inhibitor (PPI) (pantoprazole 40 mg) and a new gastro-resistant 20 mg pitolisant hydrochloride formulation in eighteen healthy subjects. Part III: Pivotal 4-way replicate design cross-over randomized, bioequivalence study of a new gastro-resistant 20 mg pitolisant hydrochloride formulation versus the reference formulation, after single oral 20 mg administration in healthy subjects. Part IV: 2-way cross-over randomized, food effect study of a new gastro-resistant 20 mg pitolisant hydrochloride formulation administered under fasting conditions and after a standard FDA High Fat Breakfast in eighteen healthy subjects.

  2023-507316-12-00· 1. fázis· Bioprojet Pharma· Forrás

• Lezárult

  Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations versus the reference pitolisant (Wakix®) tablet formulation after single oral administrations in healthy male subjects.

  2023-505769-98-00· 1. fázis· Bioprojet Pharma· Forrás

• Lezárult

  A clinical study of MK-6552 in healthy adults (MK-6552-002)

  2023-504954-37-00· 1. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.

  2023-503945-78-00· 1. fázis· Bioprojet Pharma· Forrás